AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT01814904
Drug: colestilan-H
RxNorm normalized name: colestilan
DrugBank: Colestilan chloride (DB11634)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BSAeq 9 g/day
Trial: NCT01814904
Drug: CBPB
RxNorm normalized name: Carbamazepine-10,11-epoxide
DrugBank: Carbamazepine (DB00564)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00007865
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00007865
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00730132
Drug: Ezetimibe
RxNorm normalized name: Ezetimibe
DrugBank: Ezetimibe (DB00973)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dosage determined by the investigator based on standard and applicable routine clinical practice for CHD and hypercholesterolemia patients
Trial: NCT02241551
Drug: gemcitabine/nab-paclitaxel
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: three cycles of treatment in the gemcitabine/nab-paclitaxel
Trial: NCT01115101
Drug: Oral Oxycodon
RxNorm normalized name: oxycodone Oral Solution
DrugBank: Oxycodone (DB00497)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean.
Trial: NCT01115101
Drug: Piritramid
RxNorm normalized name: Piritramida
DrugBank: Piritramide (DB12492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients assigned to the PCA group received a single use intravenous PCA device (Vygon, Medical Products, Aachen, Germany) with a 30ml deposit of 9% sodium chloride solution containing 60mg piritramide. Bolus injection of 0.5ml was administered by the patient herself if needed, with a lock out interval of 5 minutes~Patients assigned to the oral analgesia group received 20mg oxycodon at fixed intervals: 2 hours (h) and between 12h and 14h after cesarean. The PCA was discontinued after 24 hours or earlier if demanded.
Trial: NCT00797160
Drug: propofol
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 2mg/Kg IV in bolus before tracheal intubation
Trial: NCT01585623
Drug: omeprazol
RxNorm normalized name: Omeprazol
DrugBank: Omeprazole (DB00338)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:capsule~Route of administration: oral
Trial: NCT00737659
Drug: Mycophenolate mofetil (CellCept® )
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Concentration Control group: MMF dosage will be adjusted (by addition or subtraction of least 250 mg of MMF twice a day) based on MPA levels (MPA AUC target of 40 mg\*h\\L) measured on Days 7,14,Months 1,3,6 and 12.
Trial: NCT00737659
Drug: Mycophenolate mofetil (CellCept® )
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Fixed Dose group, MMF dosage will be adjusted based on standard care
Trial: NCT00440167
Drug: Gemcitabine
RxNorm normalized name: Gemcitabine
DrugBank: Gemcitabine (DB00441)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Gemcitabine 1000 mg/m², d 1, 8 , 15, q d28
Trial: NCT00440167
Drug: Erlotinib
RxNorm normalized name: Erlotinib
DrugBank: Erlotinib (DB00530)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Erlotinib 150 mg/d oral, daily without break
Trial: NCT00848536
Drug: Travoprost 0.004% (POLYQUAD-preserved) Eye Drops, Solution
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop once daily in the evening for 3 months
Trial: NCT00848536
Drug: Travoprost 0.004% (BAK-preserved) Eye Drops, Solution
DrugBank: Travoprost (DB00287)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: One drop once daily in the evening for 3 months
Trial: NCT03911037
Drug: G-CSF
RxNorm normalized name: G-CSF
DrugBank: Filgrastim (DB00099)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: G-CSF will be administered as prefilled syringes at a dosage of 5 μg/Kg subcutaneously every 12 hr for five consecutive days. Four such cycles will be administered at three monthly intervals.
Trial: NCT02220647
Drug: Linagliptin/Metformin FDC
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02220647
Drug: Linagliptin
RxNorm normalized name: Linagliptin
DrugBank: Linagliptin (DB08882)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT02220647
Drug: Metformin
RxNorm normalized name: Metformin
DrugBank: Metformin (DB00331)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Trial: NCT02448407
Drug: Hyaluronic acid
RxNorm normalized name: hyaluronic acid
DrugBank: Hyaluronic acid (DB08818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Infiltrations of Hyaluronic acid as Hyaluronate 2,5 ml, 1% solution, administered by intraarticular injections (three doses, one each fifteen days)
Trial: NCT02133989
Drug: Ticlopidine + Ginko biloba
RxNorm normalized name: Ginko biloba leaf oil
DrugBank: Ticlopidine (DB00208)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: ticlopidine hydrochloride 250mg, ginko leaf ext. 80mg, twice daily
Trial: NCT00908128
Drug: Mycophenolate Mofetil
RxNorm normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Mycophenolate Mofetil 500 mg Tablet
Trial: NCT02133989
Drug: Clopidogrel
RxNorm normalized name: Clopidogrel
DrugBank: Clopidogrel (DB00758)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: clopidogrel bisulfate 97.875mg(75mg as clopidogrel)
Trial: NCT03155503
Drug: SUVN-911
RxNorm normalized name: SUVN-502
DrugBank: SUVN-502 (DB06140)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Tablet
Trial: NCT04089553
Drug: Oleclumab
RxNorm normalized name: Oleclumab
DrugBank: Oleclumab (DB15088)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In Module 2, participants will receive oleclumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q2W of 28-day cycle for the first 4 doses and Q4W thereafter until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
Trial: NCT04089553
Drug: Durvalumab
RxNorm normalized name: Durvalumab
DrugBank: Durvalumab (DB11714)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: In Module 1 after monotherapy of AZD4635, participants will receive durvalumab 1500 mg IV (solution for infusion after dilution, 50 mg/mL) Q4W until will derive clinical benefit as judged by the investigator or until confirmed disease progression, unacceptable toxicity, started alternative anticancer therapy, withdrawal of consent, or lost to-follow-up, whichever occurs first.
Trial: NCT01701063
Drug: Telaprevir
RxNorm normalized name: Telaprevir
DrugBank: Telaprevir (DB05521)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 100- and 250-mg chewable tablets or 375-mg film-coated tablets for oral administration
Trial: NCT01701063
Drug: Peginterferon alfa-2b
RxNorm normalized name: Peginterferon alfa-2b
DrugBank: Peginterferon alfa-2b (DB00022)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 50 μg/0.5 mL, 80 μg/0.5 mL, 120 μg/0.5 mL, or 150 μg/0.5 mL for subcutaneous (SC) injection
Trial: NCT01701063
Drug: Ribavirin
RxNorm normalized name: Ribavirin
DrugBank: Ribavirin (DB00811)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200-mg capsules or 40-mg/mL solution for oral administration
Trial: NCT00356473
Drug: Atorvastatin
RxNorm normalized name: Atorvastatin
DrugBank: Atorvastatin (DB01076)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02330237
Drug: natural gels
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: whole fruits and vegetables
Trial: NCT00452920
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT01144494
Drug: Brimonidine
RxNorm normalized name: Brimonidine
DrugBank: Brimonidine (DB00484)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: One drop of brimonidine in each eye three times a day for six weeks.
Trial: NCT01144494
Drug: Artificial tears
RxNorm normalized name: Artificial Tears
DrugBank: Propylene glycol (DB01839)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lubricating drops added three times a day for six weeks
Trial: NCT02944617
Drug: VEGF-TKI
RxNorm normalized name: rhuMAb-VEGF
DrugBank: Bevacizumab (DB00112)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Must be received as standard of care chemotherapy
Trial: NCT02043132
Drug: Tranexamic Acid
RxNorm normalized name: Tranexamic Acid
DrugBank: Tranexamic acid (DB00302)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Patients randomized to TXA receive an infusion of the standard dose of Tranexamic acid (10 mg/kg) within 60 minutes prior to surgery and at wound closure. The pharmacy uses the randomization list in sequential order to determine whether that patient will receive Tranexamic acid or placebo and will provide two unlabeled IV bags (patient receives two doses) of the appropriate solution.
Trial: NCT01449188
Drug: ondansetron
RxNorm normalized name: Ondansetron
DrugBank: Ondansetron (DB00904)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved drug used to treat nausea and vomiting
Trial: NCT01585623
Drug: metoprolol
RxNorm normalized name: Metoprolol
DrugBank: Metoprolol (DB00264)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pharmaceutical form:tablet~Route of administration: oral
Trial: NCT01449188
Drug: moxifloxacin
RxNorm normalized name: Moxifloxacin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: FDA approved antibiotic commonly used as a positive control in thorough QT studies
Trial: NCT05091151
Drug: Intranasal dexmedetomidine at dose of 2 mcg/kg and 4 mcg/kg
DrugBank: Dexmedetomidine (DB00633)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Intranasal dexmedetomidine were given 45 minutes before the MRI procedure through both nostrils using a 1 mL syringe.
Trial: NCT01585623
Drug: midazolam
RxNorm normalized name: Midazolam
DrugBank: Midazolam (DB00683)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Pharmaceutical form:solution~Route of administration: oral
Trial: NCT03069183
Drug: 0.5% Ropivacaine
DrugBank: Ropivacaine (DB00296)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ultrasound-guided suprainguinal fascia iliaca compartment block with 40mls 0.5% ropivacaine.
Trial: NCT04050410
Drug: Moxonidine
RxNorm normalized name: moxonidine
DrugBank: Moxonidine (DB09242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: active drug given as 1 dose
Trial: NCT00333372
Drug: Z-338
RxNorm normalized name: Z-160
DrugBank: Z-160 (DB12743)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT04188782
Drug: Sevoflurane
RxNorm normalized name: Sevoflurane
DrugBank: Sevoflurane (DB01236)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Describe how a reiterative anesthesia exposure could induce tolerance to the anesthetic.
Trial: NCT02478775
Drug: Degarelix (GnRH antagonist)
RxNorm normalized name: Degarelix
DrugBank: Degarelix (DB06699)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist degarelix will be given subcutaneously.
Trial: NCT01148277
Drug: Propofol and Remifentnyl
RxNorm normalized name: Propofol
DrugBank: Propofol (DB00818)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intervention group (Propofol and remifentanyl): It will be administered under direct gastroenterologists' and hepatologist
Trial: NCT02554877
Drug: PF-06291874
RxNorm normalized name: PF-06291874
DrugBank: PF-06291874 (DB15065)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: study drug to be given as an oral tablet at 30, 60 or 100 mg
Trial: NCT04499677
Drug: Favipiravir
RxNorm normalized name: favipiravir
DrugBank: Favipiravir (DB12466)
FDA approved: no
EMA approved: no
PMDA approved: yes
Description: Dosage and method of administration: Day 1: 1800 mg twice daily; Day 2 to Day 7: 400 mg four (4) times daily.
Trial: NCT04499677
Drug: Lopinavir/ Ritonavir
DrugBank: Ritonavir (DB00503)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dosage and method of administration: Day 1: 400mg/100 mg twice daily; Day 2 to Day 7: 200mg/50mg four (4) times daily
Trial: NCT00274651
Drug: belinostat
RxNorm normalized name: Belinostat
DrugBank: Belinostat (DB05015)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02478775
Drug: Cetrorelix
RxNorm normalized name: Cetrorelix
DrugBank: Cetrorelix (DB00050)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Day-1: Blood samples will be obtained every 10 minutes for 10 hours. After 10 hours of blood samples have been collected, the GnRH antagonist Cetrorelix will be given subcutaneously.
Trial: NCT03139513
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Participants will receive cobimetinib as per local guidelines and/or routine clinical practice.
Trial: NCT02518945
Drug: Dapagliflozin
RxNorm normalized name: Dapagliflozin
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin or Farxiga is a SGLT-2 inhibitor
Trial: NCT02518945
Drug: Insulin
RxNorm normalized name: Insulin
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02518945
Drug: Liraglutide
RxNorm normalized name: Liraglutide
DrugBank: Liraglutide (DB06655)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Victoza(Liraglutide) is a GLP-1 agent.
Trial: NCT02518945
Drug: Dapagliflozin placebo
DrugBank: Dapagliflozin (DB06292)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: Dapagliflozin placebo looking similar to active drug Dapagliflozin in external appearance but not containing active ingredient dapagliflozin
Trial: NCT02476045
Drug: panitumumab
RxNorm normalized name: Panitumumab
DrugBank: Panitumumab (DB01269)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Maintenance treatment (ARM B)
Trial: NCT00835666
Drug: Finasteride 5 mg tablets
RxNorm normalized name: Finasteride
DrugBank: Finasteride (DB01216)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 1 x 5 mg, single dose fasting
Trial: NCT03139513
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Participants will receive vemurafenib as per local guidelines and/or routine clinical practice.
Trial: NCT00222794
Drug: Atomoxetine (Strattera)
RxNorm normalized name: atomoxetine Oral Capsule [Strattera]
DrugBank: Atomoxetine (DB00289)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03007160
Drug: Potassium Citrate Extended-release Tablets
RxNorm normalized name: Potassium Citrate Extended-Release Tablets
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Daily 3.24g, Po ,Tid, each 1.08g/tablets
Trial: NCT00864383
Drug: Moxifloxacin, Ethambutol, Isoniazid, Pyrazinamide & Rifampicin
DrugBank: Moxifloxacin (DB00218)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Moxifloxacin 400 mg Rifampicin \< 45 kg 450 mg \> 45 kg 600 mg Isoniazid 300 mg Pyrazinamide \< 40 kg 25 mg/kg rounded to nearest 500 mg\* 40-55 kg 1000 mg \> 55 kg - 75 kg 1500 mg \> 75 kg 2000 mg Ethambutol \< 40 kg 15 mg/kg rounded to nearest 100 mg 40-55 kg 800 mg \> 55 kg - 75 kg 1200 mg \> 75 kg 1600 mg \*For pyrazinamide dosing in patients \< 40 kg, 1000 mg used instead of 500 mg~All treatment is taken daily, for a duration of up to 26 weeks depending on treatment arm.
Trial: NCT01060059
Drug: exenatide
RxNorm normalized name: Exenatide
DrugBank: Exenatide (DB01276)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Trial: NCT01060059
Drug: basal insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin human (DB00030)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: subcutaneous injection, dosing according to physician's clinical judgment
Trial: NCT02341079
Drug: Bupivacaine Liposome Injection
RxNorm normalized name: bupivacaine liposome Injection
DrugBank: Bupivacaine (DB00297)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intraoperative intracapsular injection of 266mg of bupivacaine liposome injection diluted to 60mL with 0.9% normal saline.
Trial: NCT02341079
Drug: Indwelling femoral nerve block
RxNorm normalized name: Ivy Block
DrugBank: Bentoquatam (DB00516)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Femoral nerve block delivered via indwelling femoral nerve catheter with 0.125% bupivacaine.
Trial: NCT00820690
Drug: paclitaxel
RxNorm normalized name: Paclitaxel
DrugBank: Paclitaxel (DB01229)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: 4 cycles T: paclitaxel 175mg/m2 after 4 AC
Trial: NCT00654680
Drug: Vardenafil (Levitra, BAY38-9456)
RxNorm normalized name: vardenafil Oral Tablet [Levitra]
DrugBank: Vardenafil (DB00862)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 5mg, 10mg or 20mg taken 1 hour prior to sexual intercourse
Trial: NCT03965039
Drug: Stannous fluoride toothpaste
RxNorm normalized name: stannous fluoride Toothpaste
DrugBank: Stannous fluoride (DB11092)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marketed stannous fluoride (0.454%) toothpaste
Trial: NCT03965039
Drug: Potassium nitrate toothpaste
RxNorm normalized name: potassium nitrate Toothpaste
DrugBank: Potassium citrate (DB09125)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Marketed potassium nitrate (5%) toothpaste
Trial: NCT03965039
Drug: Sodium monofluorophosphate toothpaste
RxNorm normalized name: sodium monofluorophosphate Toothpaste
DrugBank: Sodium citrate (DB09154)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Marketed sodium monofluorophosphate (0.76%) toothpaste
Trial: NCT01745133
Drug: vehicle foam
RxNorm normalized name: meningococcal group B vaccine / Neisseria meningitidis serogroup B recombinant FHBP fusion protein antigen / Neisseria meningitidis serogroup B recombinant NHBA fusion protein antigen / Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle Prefilled Syringe [Bexsero]
DrugBank: Neisseria meningitidis serogroup B strain NZ98/254 outer membrane vesicle (DB10786)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: clobetasol propionate 0.05% twice a day for two weeks; then vehicle foam twice a day every day for 8 weeks
Trial: NCT01745133
Drug: calcipotriene
RxNorm normalized name: Calcipotriene
DrugBank: Calcipotriol (DB02300)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day every day for 8 weeks
Trial: NCT01745133
Drug: calcipotriene + clobetasol propionate
RxNorm normalized name: Clobetasol Propionate
DrugBank: Clobetasol propionate (DB01013)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: clobetasol propionate 0.05% twice a day for two weeks; then calcipotriene 0.005% foam twice a day on weekdays + clobetasol propionate 0.05% foam twice a day on weekends for 8 weeks
Trial: NCT01399515
Drug: Valproic Acid
RxNorm normalized name: Valproic Acid
DrugBank: Valproic acid (DB00313)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One 500mg tablet by mouth daily
Trial: NCT00681005
Drug: rabeprazole
RxNorm normalized name: Rabeprazole
DrugBank: Rabeprazole (DB01129)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 20 mg bid for 14 days
Trial: NCT00681005
Drug: pantoprazole
RxNorm normalized name: Pantoprazole
DrugBank: Pantoprazole (DB00213)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: pantoprazole 40 mg bid
Trial: NCT00012311
Drug: carboplatin
RxNorm normalized name: Carboplatin
DrugBank: Carboplatin (DB00958)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00012311
Drug: docetaxel
RxNorm normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04397094
Drug: Formocresol
RxNorm normalized name: Formocresol
DrugBank: Cresol (DB11143)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pulpotomy
Trial: NCT01109030
Drug: Pioglitazone+Citalopram+Chlordiazepoxide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Pioglitazone 15 mg every 12 hours for six weeks Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks
Trial: NCT01109030
Drug: Placebo+ Citalopram+ Chlordiazepoxide
DrugBank: Citalopram (DB00215)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Placebo 1 Q12h for 6 weeks with the same shape and color as Pioglitazone. Citalopram 20 mg per day for week one, and then 30 mg/day for 5 consecutive weeks.~Chlordiazepoxide 10 mg each night for first three weeks
Trial: NCT00107991
Drug: etanercept
RxNorm normalized name: Etanercept
DrugBank: Etanercept (DB00005)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Description: etanercept 50 mg/week subcutaneous injection
Trial: NCT00012311
Drug: etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00012311
Drug: ifosfamide
RxNorm normalized name: Ifosfamide
DrugBank: Ifosfamide (DB01181)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT00012311
Drug: thiotepa
RxNorm normalized name: Thiotepa
DrugBank: Thiotepa (DB04572)
FDA approved: yes
EMA approved: yes
PMDA approved: yes
Trial: NCT02144415
Drug: EB-1020 400 mg
RxNorm normalized name: EB-101
DrugBank: Prademagene zamikeracel (DB17895)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4 x EB-1020 100-mg capsules, and 4 matching placebo capsules
Trial: NCT01913483
Drug: Bivalirudin
RxNorm normalized name: Bivalirudin
DrugBank: Bivalirudin (DB00006)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Bivalirudin is an anticoagulant that binds directly to thrombin in a bivalent and reversible fashion.
Trial: NCT01913483
Drug: Unfractionated Heparin
RxNorm normalized name: Unfractionated heparin
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Unfractionated heparin is an anticoagulant.
Trial: NCT02036086
Drug: Vemurafenib
RxNorm normalized name: Vemurafenib
DrugBank: Vemurafenib (DB08881)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Drug
Trial: NCT02036086
Drug: Cobimetinib
RxNorm normalized name: Cobimetinib
DrugBank: Cobimetinib (DB05239)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Drug